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Abstract
Introduction: Community acquired pneumonia (CAP) is a leading cause of death worldwide.
Chronic obstructive pulmonary disease (COPD) is a well-established risk factor for development
of CAP. What is not as clear is the impact of COPD on the outcomes of patients with CAP. In this
study, we compared the outcomes of CAP in COPD and non-COPD patients.
Methods: This was a retrospective cohort study. We conducted an analysis of the Community-
Acquired Pneumonia Organization (CAPO) international cohort study database, which includes
patients with CAP admitted to several hospitals throughout the world. Patients were categorized
into two groups based on the status of COPD: COPD positive or negative. Outcomes were time
to clinical stability, length of hospital stay, and in-hospital mortality. Regression models were used
to assess the independent effect of COPD on the outcomes.
Results: This study included 7,325 patients. Of these, 1,869 (25.5%) had COPD. Patients with
COPD had higher severity of illness (pneumonia severity index class V: 15% vs 9%; P <0.001).
Accelerated failure time models with adjustment for co-variates showed no significant difference
in the probability of clinical stability (P = 0.451) and of discharge (P = 0.232) in COPD vs. non-
COPD patients. There was no difference in the crude in-hospital mortality between COPD and
non-COPD patients (9% vs 9%; P = 0.37).
Conclusion: Our study results show that COPD should not be considered a risk factor for poor
outcomes in hospitalized patients with CAP.
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1 Introduction
Community acquired pneumonia (CAP) is a major cause of death.
In 2015, lower respiratory infections were estimated to be the
third leading cause of death globally.1 The outcomes of this con-
dition are directly related to factors associated with host, causal
agent, and conditions of diagnosis and treatment. The presence
of comorbidities is the most important factor linked to poorer out-
comes.2
Chronic obstructive pulmonary disease (COPD) is a condition
characterized by persistent airflow limitation and inflammation.
It is generally progressive and associated with chronically in-
creased inflammatory response in the airways and lungs as a con-
sequence of exposure to noxious particles or gases.3 Worldwide,
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approximately 210 million people have COPD, which is consid-
ered the fourth leading cause of mortality resulting in approxi-
mately 7.8% of all deaths.4 The incidence of CAP in subjects with
COPD is estimated to be 22.4 cases per 1,000 people with COPD
per year.5
The presence of COPD as a comorbidity that affects mortality in
CAP is controversial. Some studies have found an association
with increased mortality, whereas others show no relationship
with COPD and poorer outcomes.6 Luna et al. observed a mor-
tality rate of 4.6% for CAP in individuals with no comorbidities
and 4% when associated with COPD. In this case, COPD was not
an independent factor associated with mortality.2 A case-control
study from Switzerland observed lower in-hospital mortality and
a lower rate of complications when COPD was present.7 Nonethe-
less, Torres et al. reported that asthma, smoking, chronic cardio-
vascular disease, diabetes and COPD increase the risk for pneu-
mococcal disease (CAP and invasive pneumococcal disease), and
have a detrimental effect on outcomes.8 In a study on elderly
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patients with CAP, COPD and dementia were considered inde-
pendent risk factors for admission.9 In a different study, the most
important factors contributing to higher mortality in patients with
COPD and CAP admitted to the intensive care unit (ICU) were the
presence of bilateral lung infiltrates and prolonged mechanical
ventilation, while systemic corticosteroid use and shorter length
of ICU stay seemed to be protective against a fatal outcome.10
Disease severity is also independently associated with worse out-
comes, increasing mortality and complication rates.11 In the long
term follow-up, taking into account a 5-year period after the acute
event, COPD, cardiovascular disease and malignancy were the
leading causes of death.12
Due to controversy in the literature, we conducted a study to test
the hypothesis that COPD is a risk factor for worse outcomes in
patients with CAP.
2 Methods
2.1 Study Design
This was a retrospective cohort study. We conducted an analy-
sis of the Community-Acquired Pneumonia Organization (CAPO)
international cohort study database, which is formed by a collabo-
ration of investigators throughout the world. Investigators fill out
a case report form for each case. Subsequently the data is trans-
ferred online to a HIPAA-compliant database hosted by the CAPO
study-coordinating center located at the University of Louisville in
Louisville, KY, USA. Research associates at the coordinating cen-
ter validate the cases by ensuring data quality and integrity.
Our study included adult patients who required hospitalization
for CAP from April 27, 2000 to March 13, 2016. Hospitalizations
were from Europe, Latin American, USA, and Canada. Enrollment
criteria included age ≥18 years-old and the diagnosis of CAP.
2.2 Study Definitions
CAP was defined as a new pulmonary infiltrate plus at least one
of the following: new or worsening cough, fever (T > 37.8°C or
> 100°F) or hypothermia (<35.6°C or <96°F), increased white
cell count, left shift, or decreased white cell count. For the pur-
pose of this study, "community-acquired" means the patient must
not have been hospitalized within the 2 weeks prior to the cur-
rent hospitalization. Patient was defined as having COPD if the
presence of COPD was documented in the medical record. The
availability of pulmonary function test was not a requirement for
the diagnosis of COPD.
Time to clinical stability was defined as the first day the patient
fulfilled all four criteria: cough improving, afebrile for at least 8
hours, white blood cell improving or normal, and adequate oral
intake and absorption.
2.3 Measurements
Outcomes were time to clinical stability, length of hospital stay,
and in-hospital mortality. We obtained the following vari-
ables: demographics, physiological variables (e.g. tempera-
ture), need for mechanical ventilation, need for ICU admission,
co-morbidities, smoking status, pneumonia severity index (PSI)
class,13 receipt of home infusion therapy, receipt of home wound
care, receipt of chronic dialysis within past 30 days, whether the
patient was hospitalized >2 days in the past 90 days, receipt of
intravenous antibiotics therapy in the past 90 days, and whether
the patient is a nursing home resident.
2.4 Statistical Methods
Descriptive statistics were performed on these hospitalizations.
Categorical variables were reported using frequency and percent.
Chi-Square tests were performed to compare patients with COPD
and patients without COPD for each categorical variable of in-
terest. Continuous variables were reported using median and
interquartile range (IQR). Wilcoxon Rank Sum tests were per-
formed to compare patients with COPD and patients without
COPD for each continuous variable of interest.
Kaplan Meier charts were used to compare time-to-event out-
comes between patients with COPD and patients without COPD.
Log-rank tests were performed. Logistic regression was per-
formed to find a model of best-fit predicting in-hospital mortality.
Variables used as predictors in the regression model were pres-
ence of COPD controlled by direct admission to the ICU, hospital
region, and PSI risk class.
Accelerated failure time (AFT) models were created using the log-
normal distribution for time to clinical stability and length of stay
among patients with and without COPD. Variables that were con-
trolled for each model were PSI risk class, hospital region, and
direct admission to the ICU. These models were made under the
assumption that "risk" for clinical stability and hospital discharge
change over time. Statistical significance was determined by a
P-value of less than 0.05. We used R software version 3.2.3. for
statistical analysis.14
3 Results
3.1 Patient Characteristics
A total of 7,325 patients were included in the analysis. Of these,
1,869 (25.5%) had COPD. Patients with COPD were older (me-
dian age in years [IQR]: 75 [17] vs 65 [33]; P <0.001), had more
direct admissions to the ICU (12% vs 10%; P = 0.004), required
more ventilator support (22% vs 12%; P <0.001), and had higher
severity of illness (PSI class V: 15% vs 9%; P <0.001) (see Ta-
ble 1). Patients with COPD who required mechanical ventilation
(168 [22%]) were supported predominantly through noninvasive
ventilation (123 out of 168 [73%]). Conversely, of non-COPD
patients who required mechanical ventilation (296 [12%]), half
(149 [50%]) were supported through noninvasive ventilation.
3.2 Outcomes
The median length of stay was 8 (interquartile range [IR]: 5.13)
days for patients with COPD vs 7 (IR: 5,12) days for patients with-
out COPD. Log-rank test showed patients with COPD had lower
probability of discharge over time (P < 0.001) (see Figure 1).
Time to clinical stability was similar in patients with COPD (4
days; IR: 3,8) vs patients without COPD (4 days; IR: 3,8). Log-
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Table 1 Characteristics of the patients.
COPD Non-COPD P-value
Age, median (IQR) 75 (17) 65 (33) <0.001
Gender (male), n (%) 1328 (71) 3073 (56) <0.001
Altered mental status at admission, n (%) 248 (14) 754 (14) 0.639
Oxygen saturation (%), median (IQR) 92 (7) 94 (7) <0.001
SBP (mmHg), median (IQR) 130 (35) 123 (30) <0.001
Temperature (Celsius), median (IQR) 37.2 (1.6) 37.8 (1.6) <0.001
Directly admitted to ICU, n (%) 230 (12) 540 (10) 0.004
Transferred to ICU, n (%) 49 (4) 140 (4) 0.38
Need for ventilator support day 0, n (%) 168 (22) 296 (12) <0.001
Invasive mechanical ventilation, n (%) 45 (27) 147 (50) <0.001
Non-invasive mechanical ventilation, n (%) 123 (73) 149 (50) <0.001
Alcoholic, n (%) 31 (4) 106 (4) 0.918
Cerebrovascular disease, n (%) 290 (16) 762 (14) 0.1
Diabetes, n (%) 377 (20) 980 (18) 0.035
HIV, n (%) 40 (2) 349 (6) <0.001
Liver disease, n (%) 95 (5) 322 (6) 0.203
Neoplastic Disease within the past year, n (%) 226 (12) 551 (10) 0.017
Renal disease, n (%) 225 (12) 548 (10) 0.016
Chronic renal failure, n (%) 241 (13) 480 (9) <0.001
BUN in mg/dL, Median (IQR) 35.5 (35) 31 (32) <0.001
Serum glucose mg/dl, Median (IQR) 125 (57) 119 (47) <0.001
Hematocrit (%), Median (IQR) 39 (8) 38 (7.1) <0.001
Serum sodium (mEq/L), Median (IQR) 137 (6) 136 (5) <0.001
Mortality at Discharge, n (%) 175 (9) 472 (9) 0.37
Smoking status
Current Smoker, n (%) 272 (24) 733 (20) 0.001
History of smoking, n (%) 569 (51) 909 (25) <0.001
Non-smoking history, n (%) 279 (25) 2061 (56) <0.001
Chronic dialysis within past 30 days, n (%) 6 (1) 11 (0) 0.252
Risk Class I*, n (%) 50 (3) 995 (18) <0.001
Risk Class II*, n (%) 319 (17) 1180 (22) <0.001
Risk Class III*, n (%) 533 (29) 1124 (21) <0.001
Risk Class IV*, n (%) 685 (37) 1646 (30) <0.001
Risk Class V*, n (%) 281 (15) 508 (9) <0.001
Home infusion therapy, n (%) 7 (1) 27 (1) 0.84
Home wound care, n (%) 6 (1) 24 (1) 0.829
Hospitalized >2 days in the past 90 days, n (%) 75 (10) 164 (6) 0.003
IV antibiotics therapy in the past 90 days, n (%) 60 (8) 110 (4) <0.001
Nursing home resident, n (%) 118 (6) 295 (5) 0.147
*Risk class of pneumonia severity index. 13
rank test showed that time to clinical stability curves were not
significantly different (P = 0.105) (see Figure 2). There was no
difference in the crude in-hospital mortality between COPD and
non-COPD patients (9% vs 9%; P = 0.37). Additionally, there was
no significant difference in the adjusted risk of in-hospital mortal-
ity in COPD patients (RR: 0.849; 95% CI: 0.698 - 1.032; P = 0.1)
(see Table 2).
Accelerated failure time models with adjustment for co-variates
showed no significant difference in the probability of clinical sta-
bility (P = 0.451) and of discharge (P = 0.232) (see Figures 3
and 4).
3.3 Outcomes
4 Discussion
In patients with CAP, those with COPD were older, presented with
higher severity of illness, had more direct admissions to the ICU,
and required more mechanical ventilator support. Despite these
findings, they had similar unadjusted and adjusted in-hospital
mortality and time to clinical stability. COPD patients had higher
length of hospital stay. However, the difference was no longer
significant after adjustment for co-variates. The literature is con-
sistent in showing that COPD is a risk factor for CAP,5,9 and that
this risk increases with the severity of the COPD.8 What is not as
clear is the impact of COPD on the outcomes of patients with CAP.
Jiang et al. observed more frequent ICU admissions and need
for mechanical ventilation in the COPD group; however, COPD
was not associated with a higher mortality rate.6 Similar results
were found by Liapikou et al. and Dusemund et al. where in-
hospital mortality was similar for both groups.7,15 On the other
hand, in an observational study of 710 in which all patients un-
derwent spirometry, COPD was independently associated with an
increased risk of 30-day mortality (odds ratio = 2.62 [95% CI:
1.08-6.39]).16
In our study, patients with COPD were older and had more co-
morbidities such as decompensated heart failure, renal disease,
and diabetes. Despite that, mortality rates did not differ between
groups. The finding of patients with more co-morbidities not hav-
ing worse outcomes is counterintuitive. We have four hypothet-
ical reasons that may explain our findings. First, patients with
COPD often receive systemic corticosteroids prior to and during
hospitalization with respiratory failure. Systemic corticosteroids
have been shown to be beneficial in CAP.17 The benefit of sys-
temic corticosteroids is particularly pronounced in patients with
severe CAP where a reduction in mortality by 61% was found in
a meta-analysis.18 It can be speculated that the outpatient or in-
patient use of corticosteroids for the management of COPD may
unintentionally improve CAP outcomes in these patients. Sec-
ond, the chronic lung inflammation in COPD could paradoxically
have a protective effect in these patients. In this light, our group
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Fig. 1 Kaplan-Meier curves and log-rank test comparing probability of hospital discharge between COPD and non-COPD patients.
Fig. 2 Kaplan-Meier curves and log-rank test comparing time to clinical stability between COPD and non-COPD patients.
performed a prospective observational study in 40 hospitalized
patients with CAP with the goal of characterizing their inflam-
matory response. Patients with severe CAP had higher levels of
inflammatory cytokines in the blood but lower levels of inflamma-
tory cytokines in the sputum as compared with patients with non-
severe CAP.19 The presence of chronic local inflammation could
have a protective effect against pathogen growth in the lung al-
though this is hypothetical and one could also argue that chronic
lung inflammation may lead to immune-senescence with detri-
mental effects. Third, perhaps the diagnosis of COPD prompts
physicians to take a more proactive approach in this group of pa-
tients with CAP. This proactive approach could include measures
such as closer monitoring of the respiratory status, earlier ICU ad-
mission, earlier use of non-invasive ventilation for those with hy-
percapnic respiratory failure, and a more thoughtful selection of
the antimicrobial regimen. Our study showed that patients with
COPD were more often directly admitted to the ICU, which could
reflect their higher severity of illness but also that physicians were
more cautious with this group of patients. Fourth, it is possible
that COPD patients were misdiagnosed with CAP when they ac-
tually had COPD exacerbations. The diagnosis of CAP in COPD
patients can be challenging, especially with a high frequency of
previously existing radiographic abnormalities, which could be
misleading to the clinician. As an example, a study showed that
the agreement among radiologists for the diagnosis of pneumo-
nia on the chest radiograph is only moderate (kappa = 0.53).
In the presence of COPD, the agreement is even lower (kappa =
0.20).20 Additionally, most COPD exacerbations are triggered by
an upper respiratory tract infection,21 the symptoms of which can
be similar to those of a pneumonia.
We recognize a number of limitations in our study. The main
limitation is that the diagnosis of COPD was based on a history
of COPD as outlined in the medical record. These diagnoses
therefore could have self-reported by patients (which was most
common), based on clinical suspicion, or based on spirometry. It
should be noted that a self-reported diagnosis of COPD is highly
predictive of spirometry-confirmed COPD but the absence of a
self-reported diagnosis of COPD does not substantially decrease
the likelihood of spirometry-confirmed COPD. For example, in an
accuracy study of 309 patients, a self-reported history of chronic
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Table 2 Multiple logistic regression assessing the effect of variables on in-patient mortality.
Risk Ratio (95% CI) P value
History of COPD 0.849 (0.698-1.032) 0.1
Direct ICU admission 3.047 (2.442-3.801) <0.001
Region
Europe 0.92 (0.735-1.153) 0.471
Latin America 1.788 (1.41-2.266) <0.001
Risk Class*
II 1.823 (1.093-3.042) 0.021
III 3.26 (2.013-5.279) <0.001
IV 7.555 (4.793-11.908) <0.001
V 19.15 (11.945-30.699) <0.001
*Risk class of pneumonia severity index. 13
Fig. 3 Accelerated failure time model comparing adjusted probability of discharge between COPD and non-COPD patients (dotted lines represent
95% confidence interval).
obstructive airway disease had an adjusted positive likelihood ra-
tio of 7.3 for the diagnosis of spirometry-confirmed COPD. On
the other hand, the absence of self-reported history of chronic ob-
structive airway disease had an adjusted negative likelihood ratio
of 0.5 for spirometry-confirmed COPD.22 Our study is thus sus-
ceptible to misclassification bias, which would be non-differential
and bias the effect of COPD on outcomes towards the null. Ad-
ditionally, the severity of COPD is directly related to worse out-
comes including mortality.11 Severity of COPD could not be as-
sessed in the present study because data related to pulmonary
function tests and COPD staging were not available for the ma-
jority of the patients. Another limitation is that we do not have
information on systemic and inhaled corticosteroid use, or prior
outpatient antibiotic use. Finally, we do provide information on
long-term outcomes. Our study also has a number of strengths
including a large sample size, a worldwide patient population,
which increases the external validity of the study, and the collec-
tion of several clinical and physiological variables, which allowed
for a comprehensive description of our patient population and
the ability to adjust for severity of illness in the regression analy-
ses. Future research could include studies with a cohort design in
which COPD is established by pulmonary function tests and the
impact of COPD on both short-term and long-term outcomes are
assessed. Additionally, the impact of the severity of COPD on the
outcomes of CAP should be evaluated. A better characterization
of the effect of pharmacological therapies for COPD on outcomes
of CAP is needed. For instance, what is the impact of COPD on
the outcomes of CAP after adjustment for the use of systemic cor-
ticosteroid? Is the use of inhaled corticosteroid during treatment
of CAP detrimental? Interestingly, a systematic review that in-
cluded 43 randomized clinical trials (over 30,000 patients) found
that inhaled corticosteroids increase the risk of pneumonia and
hospitalizations in patients with COPD but do not increase the
all-cause mortality in these patients.23 In summary, our study re-
sults show that in patients with CAP, those with COPD are sicker
as assessed by severity of illness and co-morbidities. Yet these
patients do not have worse short-term outcomes. Our findings
are in line with the PSI, a clinical prediction rule to risk stratify
patients with CAP that was initially prospectively validated in a
cohort of over 2,000 patients with CAP. COPD is not one of the
co-existing conditions that are part of this risk score.13 We con-
clude that COPD should not be considered a risk factor for poor
outcomes in hospitalized patients with CAP.
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